Terug naar bedrijfspagina

Nieuws over Mithra Women's Health

22/04/2024 Mithra secures court protection measures to advance monetization process (22.04.2024)

16/04/2024 Mithra - Early data from Mithra’s ESTELLE pediatric study to be presented at two upcoming congresses (16.04.2024)

08/04/2024 Mithra - reaches milestone in estetrol skin study (08.04.2024)

28/03/2024 Mithra - updates on its ongoing monetization process (28.03.2024)

08/03/2024 Mithra - reports full year 2023 financial results (08.03.2024)

05/03/2024 Mithra - announces changes to its executive management - initiates monetization process, receives bridge loan from existing lenders (05.03.2024)

28/02/2024 MITHRA - DONESTA safety study for menopause completes treatment phase and advances to data management & reporting phase (28.02.2024)

15/02/2024 Mithra - sells shares in Mayne Pharma (15.02.2024)

06/02/2024 Mithra - updates on cash position (06.02.2024)

21/12/2023 Mithra - Completes Pediatric Study of ESTELLE® in Adolescent Patients (21.12.2023)

21/12/2023 Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA in Israel (21.12.2023)

18/12/2023 Mithra - Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial (18.12.2023)

04/12/2023 Mithra - and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China (04.12.2023)

30/11/2023 Mithra - receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States (30.11.2023)

28/11/2023 Mithra - to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam (28.11.2023)

23/11/2023 Mithra - announces results of the 23 November 2023 Extraordinary General Meeting (23.11.2023)

07/11/2023 Mithra’s NEXTSTELLIS granted additional patent in the United States (07.11.2023)

31/10/2023 Mithra - Announces Results of the Special and Extraordinary General Meetings (31.10.2023)

26/10/2023 Mithra - and Searchlight Pharma sign DONESTA licensing agreement for Canada (26.10.2023)

23/10/2023 Mithra - to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement (23.10.2023)

11/10/2023 MITHRA - Letter to Shareholders (11.10.2023)

05/10/2023 Mithra - Provides an Update in the Context of Recent Market Developments (05.10.2023)

27/09/2023 Mithra - Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023 (27.09.2023)

26/09/2023 Mithra - Financial Results for First-Half 2023 (26.09.2023)

12/09/2023 MITHRA - Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855) (12.09.2023)

11/09/2023 MITHRA - Letter to Shareholders and Corporate Update (11.09.2023)

28/08/2023 Mithra - completes EUR 20 million private placement in equity Update of total number of voting rights (denominator) (28.08.2023)

08/08/2023 Mithra - and Gedeon Richter Sign Supply Agreement for Production of API for Estelle® and Donesta (08.08.2023)

03/08/2023 Mithra - Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under Estelle Licensing Agreement (03.08.2023)

31/07/2023 Mithra - and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada (31.07.2023)

15/06/2023 Mithra - Announces New Positive Preclinical Data from CSF-1R Inhibitor Program (15.06.2023)

29/05/2023 Mithra - Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman (29.05.2023)

25/05/2023 MITHRA - Letter to Shareholders and Corporate Update (25.05.2023)

11/05/2023 Mithra - announces completion of recruitment in pediatric study of Estelle in adolescent patients (11.05.2023)

04/05/2023 Mithra - and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of E4 (04.05.2023)

18/04/2023 Mithra - releases 2022 Annual Report (18.04.2023)

14/03/2023 MITHRA - Conversion of a portion of the Highbridge/Whitebox loans Information on the total number of voting rights (14.03.2023)

07/03/2023 Mithra - reports full year 2022 financial results (07.03.2023)

03/03/2023 Mithra - Announces Improved Consolidated Topline Results from Donesta® Phase 3 Studies and Launch of Recruitment for the Extension of European Study (03.03.2023)

02/03/2023 Mithra - announces compelling initial preclinical data in its research collaboration on novel tyrosine kinase inhibitors with BCI Pharma (02.03.2023)

15/02/2023 Mithra - and Richter sign a licence agreement for the commercialisation of Donesta® , the first Estetrol-based hormone therapy (15.02.2023)

02/02/2023 Mithra CDMO - announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health (02.02.2023)

13/01/2023 Mithra - and Mayne Pharma announce US launch of HALOETTE®, a generic version of NUVARING (13.01.223)

20/12/2022 MITHRA - Richter and Mithra sign binding Heads of Terms for commercialization of Donesta (20.12.2022)

17/11/2022 MITHRA - Conversion of a portion of the Highbridge/Whitebox loans and payment of the interests - Information on the total number of voting rights (denominator) - issues a put option notice under capital agreement with LDA Capital (17.11.2022)

02/11/2022 Mithra - Mithra has access to the second tranche of the Highbridge/Whitebox loan facility (31.10.2022)

24/10/2022 Mithra - and Fuji announce approval of NEXTSTELLIS in Thailand (24.10.2022)

18/10/2022 MITHRA - Conversion of a portion of the loans from Highbridge and Whitebox and information on the total number of voting rights (denominator) (18.10.2022)

17/10/2022 MITHRA - Presentation of Donesta® Phase 3 Topline Efficacy Results at the NAMS World Congress (17.10.2022)

12/10/2022 Mithra - announces positive preclinical data demonstrating Estetrol’s efficacy in wound healing (12.10.2022)

23/09/2022 Mithra - Announces 2022 Half Year Results (23.09.2022)

23/09/2022 Mithra - Conversion of a portion of the loans from Highbridge and Whitebox and information on the total number of voting rights (23.09.2022)

21/09/2022 MITHRA - AND LOTUS ANNOUNCE APPROVAL OF ALYSSA, AN INNOVATIVE ORAL CONTRACEPTIVE, IN BOTH TAIWAN AND HONG KONG (21.09.2022)

29/08/2022 MITHRA - Conversion of a portion of the loans from Highbridge and Whitebox and information on the total number of voting rights (29.08.2022)

22/08/2022 MITHRA - Conversion of a portion of the loans from Highbridge and Whitebox and information on the total number of voting rights (denominator) (22.08.2022)

08/08/2022 MITHRA - Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING (08.08.2022)

08/08/2022 Mithra - obtains funding for up to EUR 100 million from existing investors and repurchases EUR 34.1 million of its convertible bonds due 2025 at a discount to par (08.08.2022)

02/08/2022 MITHRA - NEXTSTELLIS® ORAL CONTRACEPTIVE HAS BEEN NOMINATED FOR THE 2022 PRIX GALIEN USA AWARD FOR BEST PHARMACEUTICAL AGENT (02.08.2022)

01/08/2022 Mithra - Announces Mayne Pharma’s New Direct-to-Consumer Campaign to Further Increase Awareness of NEXTSTELLIS® in the U.S. (01.08.2022)

26/07/2022 MITHRA - NEXTSTELLIS® ORAL CONTRACEPTIVE NOW AVAILABLE IN AUSTRALIA (26.07.2022)

24/06/2022 Mithra - Completes the EUR 23.5 Million Private Placement (24.06.2022)

03/06/2022 Mithra - Exercise of a Call Option from Goldman Sachs and Additional Information on the Financing Strategy (02.06.2022)

10/06/2022 2022 06 - Kansen en stoorzenders

13/05/2022 Mithra - Issues a Put Option Notice Under Capital Agreement with LDA Capital (13.05.2022)

12/05/2022 Mithra - Presentation of Donesta® Phase 3 Topline Efficacy Results at the 20th ISGE World Congress (12.05.2022)

26/04/2022 Mithra CDMO - Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection (26.04.2022)

18/04/2022 Mithra - Announces the Extension of the Capital Commitment Agreement with LDA Capital by Two Years and the Increase of the Commitment by EUR 25 million (18.04.2022)

15/04/2022 Mithra - jaarverslag 2021 (15.04.2022)

14/04/2022 Mithra - Announces Improved Consolidated Topline Results from Donesta® Phase 3 Studies and Launch of Recruitment for the Extension of European Study (14.04.2022)

21/03/2022 MITHRA - Exercise of a Second Drawing Request under Equity Funding Agreement with Goldman Sachs (21.03.2022)

08/03/2022 Mithra - Reports Full Year 2021 Financial Results (08.03.2022)

16/02/2022 Mithra - and Searchlight Pharma Announce Launch of Haloette® in Canada (16.02.2022)

07/02/2022 Mithra - Obtains Equity Funding for up to EUR 100 Million (07.02.2022)

14/01/2022 Mithra - Announces Positive Top-Line Results from Donesta® Phase 3 Studies in Menopausal Women (14.01.2022)

29/11/2021 Mithra - MAYNE PHARMA AND MITHRA ANNOUNCE TGA APPROVAL OF NEXTSTELLIS® ORAL CONTRACEPTIVE (29.11.2021)

21/10/2021 Mithra - Announces Estelle® Launch in Belgium (21.10.2021)

06/10/2021 Mithra - annonce un update de la FDA concernant Myring

24/09/2021 Mithra kondigt halfjaarresultaten 2021 aan - Topline Results for COVID-19 Phase II Study (24.09.2021)

21/09/2021 Mithra - Donesta® Phase III: Recruitment Completion of American Study and Additional Recruitment in the European Study (21.09.2021)

16/09/2021 Mithra - Announces Estelle® Approval in Russia (16.09.2021)

15/09/2021 Mithra - and Searchlight Pharma Announce Availability of Nextstellis® in Pharmacies Across Canada (15.09.2021)

15/07/2021 Mithra - ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments (15.07.2021)

24/06/2021 Mithra - successfully renegotiates the earnouts relating to its Complex Therapeutics and acquires full licensing and distribution rights for Zoreline (24.06.2021)

21/06/2021 Mithra - ESTELLE® ORAL CONTRACEPTIVE NOW AVAILABLE IN THE UNITED STATES (21.06.2021)

17/06/2021 Mithra - Completes Recruitment of Covid-19 Phase II Study (17.06.2021)

27/05/2021 Mithra - Nextstellis Receives FDA Marketing Exclusivity and Phase III Data Published (27.05.2021)

25/05/2021 Mithra: gewapend met Estelle en Donesta

20/05/2021 Mithra’s - General Meeting of Shareholders Approves the Renewal of its Board of Directors (20.05.2021)

20/05/2021 Mithra - Announces European Approval of Estelle® (20.05.2021)

05/05/2021 Mithra: "Donesta kan een grotere blockbuster worden dan Estelle"

29/04/2021 Mithra - takes note of François Fornieri’s indictment (29.04.2021)

20/04/2021 Mithra Releases 2020 Annual Report and Invitation to its Securities holders’ Meeting (20.04.2021)

16/04/2021 MITHRA - AND MAYNE PHARMA ANNOUNCE FDA APPROVAL OF NEW ORAL CONTRACEPTIVE ESTELLE® (16.04.2021)

16/04/2021 Mithra: Estelle maakt zich op voor geboorte in juni

26/03/2021 Mithra - Richter and Mithra Receive Positive CHMP Opinion for Estelle® (26.03.2021)

09/03/2021 Mithra - Annual-Results-EN (09.03.2021)

08/03/2021 Mithra en Searchlight Pharma kondigen (08.03.2021)

02/03/2021 Mithra - Launch-Myring-Italy-EN (02.03.2021)

09/02/2021 Mithra - 2021-02-09-Publication-in-Contraception-EN (09.02.2021)

23/12/2020 Mithra - Richter and Mithra strengthen their partnership and signed a license and supply agreement for the commercialization of Estelle (23.12.2020)

11/12/2020 Mithra - announces final terms of its offering of EUR 125 million convertible bonds due 2025 (10.12.2020)

10/12/2020 Mithra - launches an offering of up to EUR 150 million convertible bonds due 2025 (10.12.2020)

03/12/2020 Mithra - Scientific community convinced of Estetrol's potential for women's health (3.12.2020)

30/11/2020 Mithra - exclusivity on Estetrol applications extended to 2036 in Europe (30.11.2020)

25/11/2020 Mithra - Estetrol recognized as a "New Active Substance" by the European Medicines Agency (25.11.2020)

03/11/2020 Mithra - Renews its Board of Directors to Support its Operational Ambitions (3.11.2020)

19/10/2020 Mithra - Signs LSA for Commercialization of Estelle in North Africa (19.10.2020)

06/10/2020 Mithra - Announces FDA update (6.10.2020)

24/09/2020 Mithra - Announces 2020 Half Year Results (24.9.2020)

20/08/2020 Mithra - Announces Commercial Launch of Myring™ in the Netherlands (19.8.2020)

04/08/2020 Mithra - announces shelf life extension for Myring to 36 months (4.8.2020)

30/07/2020 Mithra - Announces Commercial Launch of Tibelia® (30.7.2020)

23/07/2020 Mithra - EGM Approves Warrant Plan for LDA Capital (23.7.2020)

14/07/2020 Mithra - Signs License and Supply Agreement for Commercializationof Myring™ in Mexico (14.7.2020)

06/07/2020 Mithra - Signs LSA for Commercialization of Myring™ in France, Poland and United Kingdom (6.7.2020)

24/06/2020 Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle in the US (24.6.2020)

18/06/2020 Mithra Launches Capital Increase By Means of a Private Placement (18.6.2020)

11/06/2020 Mithra Signs LSA for Commercialization of Tibelia (11.06.2020)

05/06/2020 Mithra - Issues First Put Option Notice Under Capital Agreement with LDA Capital (5.6.2020)

28/05/2020 Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia

20/05/2020 Mithra and Searchlight Pharma Announce Filing for Canada (20.5.2020)

05/05/2020 Mithra - and Gynial Sign Commercialization Agreement for Myring™ in Switzerland (5.5.2020)

24/04/2020 Mithra - Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital (24.4.2020)

02/04/2020 Mithra Announces Commercial Launch of Myring™ in Germany the biggest market in Europe (2.4.2020)

02/04/2020 Mithra Announces Donesta® Phase III Clinical Program Update (1.4.2020)

09/03/2020 Mithra vervelt tot farmaspeler, maar dat kost geld

09/03/2020 Mithra - Reports Full Year 2019 Financial Results (9.3.2020)

03/03/2020 Mithra mag Estelle vermarkten in België en Luxemburg (03.03.2020)

12/02/2020 Mithra - Announces Commercial Launch of Myring™ in Belgium (12.2.2020)

10/02/2020 Mithra - Mithra receives positive ruling on Patent Income Deduction (10.2.2020)

21/01/2020 Mithra - Signs LSA for Commercialization of Myring™ in Italy (21.1.2020)

15/01/2020 Mithra - Announces 2020 Financial Calendar (15.1.2020)

10/01/2020 Mithra - E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines (10.1.2020)

07/01/2020 Mithra - Signs License and Supply Agreement for Commercialization of Tibelia® (7.1.2020)

06/01/2020 Mithra - Signs LSA with Alvogen for Commercialization of Estelle® in Hong Kong and Taiwan(6.1.2020)

27/12/2019 Mithra - Information on the Total Number of Voting Rights (Denominator) (24.12.2019)

23/12/2019 Mithra Receives EUR 2.9 Million in Non-dilutive Funding (23.12.2019)

16/12/2019 Mithra and Searchlight sign LSA for Myring™ in Canada (16.12.2019)

05/12/2019 Mithra - Signs LSA for Commercialization of Myring™ in Switzerland (5.12.2019)

08/11/2019 Mithra - European Authorities Approve Advantageous Modifications to Myring™ labelling (8.11.2019)

30/10/2019 Mithra -Notice of Extraordinary Shareholders Meeting on 29th November 2019 (30.10.2019)

22/10/2019 Mithra Announces Publication of Estelle® Abstracts in Connection with Meeting European Society of Gynecology '22.10.2019)

14/10/2019 Mithra Signs Agreement for Commercialization of Myring in China with Abbott(14.10.2019)

09/10/2019 Mithra Initiates Phase III Clinical Program for Donesta (9.10.2019)

04/10/2019 Mithra Provides Supplementary Details on Estelle® US Deal with Mayne (3.10.2019)

02/10/2019 Mithra: Niet beloond voor keuze Amerikaanse Estelle partner (KBC)

19/09/2019 Mithra - halfjaarresultaten 2019 (19.9.2019)

19/09/2019 Mithra: stoomt rustig door (KBC)

20/08/2019 Mithra - Signs LSA for Commercialization of Estelle® and Myring™ in Israel (20.8.2019)

08/08/2019 Mithra - obtains crucial additional Estelle® patent in Japan (8.8.2019)

16/07/2019 Mithra - CDMO Strengthens its Management Team and Accelerates Key R&D Programs (16.7.2019)

26/06/2019 Beleggen in biotech is 'risky business' (Test-Aankoop invest)

15/05/2019 Mithra - Tibelia-First Tibolone-Based Hormone Therapy Approved in Canada (15.5.2019)

25/04/2019 Wereldhave Belgium trading update (25.4.2019)

25/04/2019 Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America (25.4.2019)

18/04/2019 Mithra - new agreement with GSP for development of an additional injectable (18.4.2019)

02/04/2019 Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle (2.4.2019)

02/04/2019 Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment (2.4.2019)

25/03/2019 Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society (25.3.2019)

05/03/2019 Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile (5.03.19)

01/03/2019 Mithra Reports 2018 Annual Results (1.3.2019)

28/02/2019 Mithra Signs Partnership Agreement With Itrom for Commercialization of Estelle® in the Middle East (28.2.2019)

20/02/2019 Mithra Announces New Polymer Technology Development (20.2.2019)

13/02/2019 Mithra Successfully Produces its First Commercial Batch oi Myring for Europe (13.2.2019)

12/02/2019 Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East (12.2.2019)

04/02/2019 Mithra Strengthens Management Team with Key Appointments (4.2.2019)

30/01/2019 Mithra Announces Positive Top-line Results of Estelle (30.1.2019)

22/01/2019 Mithra announces 2019 financial calendar (22.1.2019)

18/01/2019 Mithra Wins BelMid Company of the Year 2018 (18.1.2019)

07/01/2019 Biocartis doet wat moet: groeien; Mithra timmert (zelf) aan de pijplijn (KBC)

07/01/2019 Mithra-Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program (7.1.2019)

04/01/2019 Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference (4.1.2019)

21/12/2018 Mithra announces complex therapeutics update (21.12.2018)

06/12/2018 Mithra Announces Positive Results of Ovarian Function Sub-Study which Strengthens Estelle® Contraceptive Efficacy Profile (6.12.2018)

20/11/2018 MITHRA SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR VAGINAL CONTRACEPTIVE RING IN AUSTRALIA AND NEW ZEALAND (20.11.2018)

19/11/2018 Mithra-FULL ESTETROL (E4) PROGRAM UPDATE PROVIDED AT SCIENTIFIC ADVISORY BOARD MEETINGS (19.11.2018)

14/11/2018 Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle (14.11.2018)

06/11/2018 Mithra-New Warrant Plan Approved by Mithra Shareholders (6.11.2018)

10/10/2018 Mithra-2018 Update and 2019 Outlook Given at the CPHI Conference (10.10.2018)

05/10/2018 Mithra Women's health-Notice of 2018 Extraordinary General Meeting (5.10.2018)

03/10/2018 Mithra-Presentation of Donesta PhIIb Results at the 2018 Annual Meeting of the North American Menopause Society (3.10.2018)

27/09/2018 MITHRA SIGNS AGREEMENT FOR THE COMMERCIALIZATION OF MYRING™ IN CHILE WITH LABORATORIO PASTEUR (27.9.2018)

25/09/2018 MITHRA ANNOUNCES 2018 HALF YEAR RESULTS (25.9.2018)

21/09/2018 Mithra signs exclusive license and supply agreement for commercialization of Tibelia® in Taiwan (21.9.2018)

12/09/2018 Mithra and Richter Sign License and Supply Agreement for Commercialization of Estelle®, a Novel Oral Contraceptive (12.9.2018)

08/08/2018 Mithra Announces Positive Top-Line Results of Estelle® Phase III Oral Contraceptive Study in EU and Russia (8.8.2018)

08/02/2018 Mithra verstevigt Estelle-front (KBC Group)